MIRM - Mirum stock climbs after positive interim data from liver disease drug
2024-06-17 13:26:03 ET
More on Mirum Pharmaceuticals
- Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript
- Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
- Mirum Pharmaceuticals GAAP EPS of -$0.54 misses by $0.14, revenue of $69.2M misses by $0.97M
- Mirum Pharmaceuticals Q1 2024 Earnings Preview
- Seeking Alpha’s Quant Rating on Mirum Pharmaceuticals